A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

NCT05360160 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: SNDX-5613
DRUG: Venetoclax
DRUG: ASTX727

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]